Can You Take Zetia (Ezetimibe) With Hormonal Contraceptives?

Pharmacokinetic Basis of the Interaction

Ezetimibe is absorbed in the small intestine, then extensively conjugated to ezetimibe-glucuronide via UGT1A1, UGT1A3, and UGT2B15 in the intestinal wall and liver 1. This glucuronide conjugate is the primary circulating active metabolite, accounting for roughly 80-90% of total drug exposure in plasma. Ethinyl estradiol, the estrogen component in most combined oral contraceptives, is also a substrate for UGT1A1-mediated glucuronidation 2.

The overlap at UGT1A1 creates the theoretical basis for a pharmacokinetic interaction. Both compounds compete for the same conjugation pathway, which could slow the metabolism of either drug. The FDA-approved prescribing information for Zetia reports that coadministration with a combined oral contraceptive containing ethinyl estradiol and levonorgestrel increased the AUC of ethinyl estradiol by approximately 10% and levonorgestrel by approximately 10% 3. These increases fall well below the 25% threshold that typically triggers clinical concern for hormonal contraceptive interactions per FDA bioequivalence guidance 4.

Ezetimibe does not inhibit or induce cytochrome P450 enzymes (CYP1A2, CYP2C8, CYP2C9, CYP2D6, CYP3A4) at clinically relevant concentrations 3. This is significant because CYP3A4 is the dominant oxidative pathway for ethinyl estradiol 5. Drugs that induce CYP3A4 (rifampin, certain anticonvulsants) are the classic contraceptive-efficacy reducers. Ezetimibe does not share that mechanism.

Clinical Significance: What the Data Actually Show

The interaction between ezetimibe and hormonal contraceptives is classified as minor in standard drug-drug interaction databases. A 10% increase in ethinyl estradiol AUC is within normal inter-individual variability for oral contraceptive pharmacokinetics, which can range 40-50% depending on food intake, gut motility, and enterohepatic recirculation 6.

No published case reports document contraceptive failure attributable to ezetimibe coadministration. For comparison, the Endocrine Society's 2017 clinical practice guideline on lipid management in endocrine practice notes that ezetimibe has a favorable drug interaction profile compared to bile acid sequestrants, which can physically bind and reduce absorption of oral contraceptives if taken concurrently 7.

The modest estrogen-exposure increase could theoretically raise the risk of estrogen-related adverse effects (headache, breast tenderness, nausea) in susceptible patients. One concern is venous thromboembolism (VTE). Combined oral contraceptives already carry a baseline VTE risk of 3-9 per 10,000 woman-years versus 1-5 per 10 to 000 in non-users, per WHO data 8. A 10% increase in ethinyl estradiol exposure is unlikely to meaningfully shift this risk, though no dedicated VTE outcome study has been conducted for the specific ezetimibe-OC combination.

Who Needs This Combination and Why It Matters

Women of reproductive age with heterozygous familial hypercholesterolemia (HeFH) represent the most common clinical scenario for concurrent ezetimibe and contraceptive use. HeFH prevalence is approximately 1 in 250 individuals worldwide 9. Many of these patients require lipid-lowering therapy starting in early adulthood. Reliable contraception is simultaneously needed because statins (often coprescribed with ezetimibe) are contraindicated in pregnancy.

The IMPROVE-IT trial (N=18,144) demonstrated that adding ezetimibe 10 mg to simvastatin 40 mg reduced LDL cholesterol by an additional 24% versus simvastatin alone and lowered the composite cardiovascular endpoint from 34.7% to 32.7% over a median 6-year follow-up 10. Subgroup analyses showed consistent benefit across sex, making the ezetimibe-statin combination a standard regimen for both men and women with atherosclerotic cardiovascular disease risk.

For women who cannot tolerate statins, ezetimibe monotherapy reduces LDL by approximately 18% 10. The 2018 AHA/ACC cholesterol guideline lists ezetimibe as a recommended add-on when statin therapy alone does not achieve sufficient LDL reduction 11. This means a sizeable population of premenopausal women may be taking both drugs long-term.

Progestin-Only Contraceptives: A Separate Consideration

The formal pharmacokinetic study in the Zetia label specifically evaluated a combined pill containing ethinyl estradiol and levonorgestrel 3. Data on progestin-only methods (the minipill, etonogestrel implant, levonorgestrel IUD, depot medroxyprogesterone acetate) are limited but can be extrapolated based on pharmacologic principles.

Progestin-only contraceptives bypass the ethinyl estradiol component entirely. Levonorgestrel is primarily metabolized by CYP3A4 with some contribution from CYP3A5, not predominantly by glucuronidation 12. Since ezetimibe does not meaningfully affect CYP3A4 activity, the interaction potential with progestin-only contraceptives is even lower than with combined pills.

The levonorgestrel IUD (Mirena, Liletta) delivers hormone locally to the uterus with minimal systemic absorption (serum levonorgestrel levels roughly 150-200 pg/mL versus 3,000-5,000 pg/mL with oral levonorgestrel) 13. Any pharmacokinetic interaction with ezetimibe at the glucuronidation level would be clinically irrelevant at these low systemic concentrations. For patients concerned about any interaction whatsoever, a levonorgestrel IUD or etonogestrel implant effectively eliminates the question.

Liver Enzyme Monitoring When Both Drugs Are Used

Both hormonal contraceptives and ezetimibe can affect hepatic transaminases. Ethinyl estradiol-containing contraceptives are associated with rare cholestatic hepatotoxicity 14. Ezetimibe monotherapy rarely elevates ALT, but the combination of ezetimibe with a statin increases the rate of transaminase elevation above 3 times the upper limit of normal to approximately 1.3% versus 0.4% with statin alone, per pooled trial data 3.

The practical recommendation is straightforward. Check ALT and AST at baseline, repeat at 12 weeks after starting the combination, then annually. If transaminases rise above 3 times the upper limit of normal, discontinue ezetimibe first and reassess. The contraceptive is far less likely to be the cause, and maintaining reliable contraception is critical if the patient is also on a statin.

"We routinely check liver function at baseline and at 3 months in patients starting ezetimibe-statin combination therapy, particularly in women on oral contraceptives, because the additive hepatic metabolism load warrants early surveillance," notes the AACE 2020 consensus statement on dyslipidemia management 15.

Lipid Panel Interpretation During Concurrent Use

Hormonal contraceptives alter the lipid profile independently of ezetimibe therapy. Ethinyl estradiol raises HDL cholesterol by 10-15% and triglycerides by 20-30%, while the progestin component (depending on its androgenicity) may partially offset the HDL increase 16. This creates a confounded lipid panel when clinicians try to assess ezetimibe efficacy.

A common mistake is attributing an unexpectedly high triglyceride level to ezetimibe failure when the oral contraceptive is the actual driver. Ezetimibe reduces LDL by 15-22% but has minimal effect on triglycerides 10. If a patient on both medications shows an LDL decrease but triglyceride increase, the pattern is pharmacologically expected and does not indicate treatment failure.

For accurate LDL monitoring, obtain fasting lipid panels at the same point in the contraceptive cycle (ideally during the active-pill phase) to reduce variability. Non-HDL cholesterol or apolipoprotein B may be more reliable tracking metrics than LDL-C alone in this setting, as recommended by the 2019 ESC/EAS dyslipidemia guidelines 17.

Bile Acid Sequestrants: The Contraceptive Interaction to Watch

While ezetimibe poses minimal risk to contraceptive efficacy, bile acid sequestrants (cholestyramine, colesevelam, colestipol) are a different story. These resins bind drugs nonselectively in the gut and can reduce oral contraceptive absorption by 30-40% if taken simultaneously 7. Patients sometimes switch between lipid-lowering agents, and this distinction matters.

If a patient transitions from ezetimibe to a bile acid sequestrant, the contraceptive should be taken at least 1 hour before or 4 hours after the resin. This timing separation is not necessary with ezetimibe. The prescribing information for colesevelam (Welchol) specifically warns about reduced bioavailability of ethinyl estradiol and norethindrone when coadministered 18.

Patient Counseling Points

Tell patients three things. First, ezetimibe does not reduce the effectiveness of their birth control. Second, take both medications at their usual times without special spacing. Third, report any new symptoms of right upper quadrant abdominal pain, unusual fatigue, or jaundice, as these could indicate hepatic stress warranting liver enzyme testing.

For patients on a statin-ezetimibe combination (Vytorin or separate pills), emphasize the pregnancy contraindication of the statin component. The FDA's 2021 labeling update removed the blanket contraindication for statins in all women of reproductive age but maintained the recommendation to discontinue statins during pregnancy and in those planning pregnancy 19. Reliable contraception while on statins remains standard clinical guidance per AHA/ACC recommendations 11.

"The statin pregnancy contraindication is the real reason contraception matters in this population. The ezetimibe-contraceptive interaction itself is not a clinical concern at standard doses," per the ACC's 2022 Expert Consensus Decision Pathway on the role of nonstatin therapies 20.

Ezetimibe 10 mg can be taken at any time of day, with or without food, and does not need to be separated from the oral contraceptive pill by any specific interval 3.